Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients: An Observational Cross-Sectional Study

Data on use of monoclonal antibodies (mAbs) in hospitalized patients are limited. In this cross-sectional study, we evaluated the use of mAbs for early treatment of unvaccinated hospitalized patients with mild-to-moderate COVID-19. All inpatients at our center were screened on 27 October 2021. Prima...

Full description

Bibliographic Details
Published in:	Antibiotics
Main Authors:	Sean W. X. Ong, Dongdong Ren, Pei Hua Lee, Stephanie Sutjipto, Christopher Dugan, Bo Yan Khoo, Jun Xin Tay, Shawn Vasoo, Barnaby E. Young, David C. Lye
Format:	Article
Language:	English
Published:	MDPI AG 2022-03-01
Subjects:	COVID-19 SARS-CoV-2 sotrovimab treatment monoclonal antibody
Online Access:	https://www.mdpi.com/2079-6382/11/3/345

Similar Items

Characteristics and outcomes of COVID-19 patients presumed to be treated with sotrovimab in NHS hospitals in England
by: Vishal Patel, et al.
Published: (2024-04-01)

Outcomes of pregnant women exposed to Sotrovimab for the treatment of COVID-19 in the BA.1 Omicron predominant era (PRESTO)
by: Jessica J. Tuan, et al.
Published: (2023-04-01)

Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19
by: Federico Baldi, et al.
Published: (2023-01-01)

Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the USA
by: Mindy M. Cheng, et al.
Published: (2023-01-01)

Effectiveness of Sotrovimab in the Omicron Storm Time: A Case Series
by: Gaetano Cicchitto, et al.
Published: (2022-12-01)

Clinical Efficacy of the Neutralizing Antibody Therapy Sotrovimab in Patients with SARS-CoV-2 Omicron BA.1 and BA.2 Subvariant Infections
by: Naoyuki Miyashita, et al.
Published: (2023-05-01)

Assessment of symptoms in COMET-ICE, a phase 2/3 study of sotrovimab for early treatment of non-hospitalized patients with COVID-19
by: Sacha Satram, et al.
Published: (2023-09-01)

Treatment of persistent COVID-19 in two B-cell-depleted patients with the monoclonal antibody Sotrovimab
by: David Totschnig, et al.
Published: (2022-01-01)

Sotrovimab lost neutralization efficacy against SARS-CoV-2 subvariants but remained clinically effective: Were monoclonal antibodies against COVID-19 rejected too early?
by: Line Lundegaard Bang, et al.
Published: (2024-09-01)

Sotrovimab: una opción terapéutica en trasplante pulmonar
by: Rosa Gutiérrez-Larraya-Sánchez-Andrade, et al.
Published: (2024-01-01)

Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life
by: Luca Cegolon, et al.
Published: (2023-05-01)

Early Use of Sotrovimab in Children: A Case Report of an 11-Year-Old Kidney Transplant Recipient Infected with SARS-CoV-2
by: Costanza Di Chiara, et al.
Published: (2022-03-01)

Safety Profile and Outcomes of Early COVID-19 Treatments in Immunocompromised Patients: A Single-Centre Cohort Study
by: Simona Biscarini, et al.
Published: (2022-08-01)

Optimizing COVID-19 treatment in immunocompromised patients: early combination therapy with remdesivir, nirmatrelvir/ritonavir and sotrovimab
by: Ivan Gentile, et al.
Published: (2023-12-01)

Treatment with Sotrovimab and Casirivimab/Imdevimab Enhances Serum SARS-CoV-2 S Antibody Levels in Patients Infected with the SARS-CoV-2 Delta, Omicron BA.1, and BA.5 Variants
by: Kana Fujimoto, et al.
Published: (2022-12-01)

Real world effectiveness of sotrovimab in preventing COVID-19–related hospitalisation or death in patients infected with Omicron BA.2
by: Alwaleed Behzad, et al.
Published: (2024-02-01)

Sotrovimab-emergent resistance in SARS-CoV-2 Omicron: A series of three cases
by: Daniele Focosi, et al.
Published: (2022-08-01)

Remdesivir Versus Sotrovimab in Coronavirus Disease 2019: A Systematic Review and Meta‐Analysis
by: Saeed Khorramnia, et al.
Published: (2025-07-01)

Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants
by: Daniele Focosi, et al.
Published: (2024-01-01)

Implementing Early Phase Treatments for COVID-19 in Outpatient Settings: Challenges at a Tertiary Care Center in Italy and Future Outlooks
by: Tommaso Manciulli, et al.
Published: (2022-04-01)

Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern
by: Fulvia Mazzaferri, et al.
Published: (2022-11-01)

Comparison of effectiveness and safety of molnupiravir versus sotrovimab for COVID‐19: A systematic review and meta‐analysis
by: Bahman Amani, et al.
Published: (2024-04-01)

Real-world evidence of sotrovimab effectiveness for preventing severe outcomes in patients with COVID-19: A quality improvement propensity-matched retrospective cohort study of a pan-provincial program in Alberta, Canada
by: Gregory Farmer, et al.
Published: (2024-09-01)

Use of Sotrovimab for COVID-19 in a Patient with International Germ Cell Consensus Classification Poor Prognosis Testicular Germ Cell Tumor
by: Hirotaka Nagasaka, et al.
Published: (2023-09-01)

Efficacy of Remdesivir and Neutralizing Monoclonal Antibodies in Monotherapy or Combination Therapy in Reducing the Risk of Disease Progression in Elderly or Immunocompromised Hosts Hospitalized for COVID-19: A Single Center Retrospective Study
by: Davide Fiore Bavaro, et al.
Published: (2023-05-01)

Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single-centre study
by: I. Gentile, et al.
Published: (2025-12-01)

Immune-related adverse events of biological immunotherapies used in COVID-19
by: Daniela Baracaldo-Santamaría, et al.
Published: (2022-08-01)

Comparable outcomes of outpatient remdesivir and sotrovimab among high-risk patients with mild to moderate COVID-19 during the omicron BA.1 surge
by: Supavit Chesdachai, et al.
Published: (2024-03-01)

SARS-CoV-2 Pre-Exposure Prophylaxis with Sotrovimab and Tixagevimab/Cilgavimab in Immunocompromised Patients—A Single-Center Experience
by: David Totschnig, et al.
Published: (2022-10-01)

Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar
by: Ahmed Zaqout, et al.
Published: (2022-11-01)

Monoclonal Antibodies in Prevention and Early Treatment of COVID-19 in Lung Transplant Recipients: A Systematic Review and Perspective on the Role of Monoclonal Antibodies in the Future
by: David A. Van Eijndhoven, et al.
Published: (2025-02-01)

In Vitro and In Vivo Neutralizing Efficacy of Monoclonal Antibodies Against Sars-Cov-2 Variants in Kidney Transplant Recipients
by: Ilies Benotmane, et al.
Published: (2024-07-01)

Unveiling therapeutic dynamics: An in-depth comparative analysis of neutralizing monoclonal antibodies and favipiravir in alleviating COVID-19 outpatients impacts among middle-aged and special populations (MA-FAST)
by: Taweegrit Siripongboonsitti, et al.
Published: (2024-07-01)

What Is the Efficacy of Sotrovimab in Reducing Disease Progression and Death in People with COVID-19 during the Omicron Era? Answers from a Real-Life Study
by: Andrea De Vito, et al.
Published: (2023-08-01)

Sotrovimab retains activity against SARS-CoV-2 omicron variant BQ.1.1 in a non-human primate model
by: Cécile Hérate, et al.
Published: (2023-06-01)

Efficacy of Sotrovimab (SOT), Molnupiravir (MOL), and Nirmatrelvir/Ritponavir (N/R) and Tolerability of Molnupiravir in Outpatients at High Risk for Severe COVID-19
by: Victoria Kauer, et al.
Published: (2023-05-01)

Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals, or no treatment: a retrospective cohort study
by: Myriam Drysdale, et al.
Published: (2024-07-01)

Effect of Bamlanivimab as Monotherapy or in Combination with Etesevimab or Sotrovimab on Persistently High Viral Load in Patients with Mild-to-Moderate COVID-19: A Randomized, Phase 2 BLAZE-4 Trial
by: Russell M. Nichols, et al.
Published: (2024-01-01)

Efficacy and Safety of Sotrovimab Versus Oral Antiviral for Early Treatment in High-Risk Patients in Omicron Era: A Multicenter Retrospective Study
by: Antonio Russo, et al.
Published: (2025-02-01)

Monitoring of Sotrovimab-Levels as Pre-Exposure Prophylaxis in Kidney Transplant Recipients Not Responding to SARS-CoV-2 Vaccines
by: Constantin Aschauer, et al.
Published: (2023-07-01)